Ignoring China's biotech industry is no longer an option. It's a recipe for disaster

Big Pharma has a habit of clustering around drug targets. So it was business as usual when GSK stepped in Monday morning to pick up an early-stage PDE3/4 inhibitor on the heels of Merck’s ...